Veteran finance expert Tristan Ribar is the new vice president of corporate finance and treasury at NuVasive, Inc.
Tristan Ribar: New VP, Finance, Treasury at NuVasive

According to the company, “Ribar oversees the NuVasive Corporate Finance and Treasury functions, including financial planning and analysis, treasury operations, along with supporting investor relations.”
“Mr. Ribar has strong finance and financial planning and analysis experience in the medtech industry which includes his most recent position at Alere, where he led the budgeting, forecasting, reporting and business analysis for the company before it was acquired by Abbott Laboratories in October 2017.”
“Prior to that, he was the director of investor relations at CareFusion where he previously held multiple finance leadership roles within the organization since its spin-off from Cardinal Health, as well as leading the finance integration when the company was acquired by Becton Dickinson in March 2015.”
“Ribar earned a Bachelor of Science in business and a master of business administration from Ohio Dominican University in Columbus, Ohio.”
“With these new leadership appointments, along with the rest of the finance team, we are building out the depth of the function through an excellent mix of finance and operations prowess as we focus on key areas to drive growth for NuVasive,” said Raj Asarpota, executive vice president and chief financial officer of NuVasive. “Specifically, this growth will be supported by our insourcing efforts at our manufacturing facility where we will continue to invest in the processes, tools and people with the financial expertise in costing and productivity enhancement to accelerate our profitability.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.